Previous 10 | Next 10 |
ImmunityBio has finally submitted the Anktiva (N-803) and BCG combination BLA in NMIBC ahead of the final clinical results presentation at ASCO. The company is still moving forward with multiple cancer and infectious disease programs with Anktiva. An FDA approval would improve the out...
ImmunityBio (NASDAQ:IBRX) said it submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of N-803 plus Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 di...
Results for this FDA-designated Breakthrough Therapy exceed historical complete response rates and duration of response of current approved therapies for this indication ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced it has su...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ...
Data from ImmunityBio’s QUILT 3.032 BCG-unresponsive non-muscle invasive bladder cancer trial will be presented by principal investigator in an oral presentation Poster presentation of QUILT 88 pancreatic data ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage imm...
Novel combination therapy of Anktiva, an IL-15 superagonist, and Keytruda targeted at patients with lung cancer who have failed checkpoint inhibitor therapy The study currently includes nearly 200 U.S. sites and will involve 478 patients when fully enrolled Nearly 237,000 new ...
There's a good amount of work going into another generation of coronavirus vaccines that could have broader activity against more coronaviruses, but this is going to be taking us up to the edge of what we think is possible in the field. The coronavirus family that we know and love is ...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren’t found and...
Shares of ImmunityBio Inc. (NASDAQ:IBRX) traded today at $40.56, eclipsing its 52-week high. This new high was reached on above average trading volume as 26.9 million shares traded hands, while the average 30-day volume is approximately 1.3 million shares. ImmunityBio Inc. has overhead s...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the QUILT-3.032 study completing at least 12 months of follow-up as of January 14, 2022. All data for QUILT-3.032, which is studying ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...